Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 406

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

Open access
Kewalramani, Tarun, Zelenetz, Andrew D., Nimer, Stephen D., Portlock, Carol, Straus, David, Noy, Ariela, O'Connor, Owen, Filippa, Daniel A., Teruya-Feldstein, Julie, Gencarelli, Alison, Qin, Jing, Waxman, Alyson, Yahalom, Joachim, Moskowitz, Craig H.·2004·Blood
DOI 10.1182/blood-2003-11-3911
Open this paper in CoChat — free account

Abstract

Patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) who achieve complete response (CR) before autologous stem cell transplantation (ASCT) generally have better outcomes than those who achieve only partial response (PR). We investigated whether adding rituximab to the ifosfamide-carboplatin-etoposide (ICE) chemotherapy regimen (RICE) could increase the CR rate of patients with DLBCL under consideration for ASCT. Thirty-six eligible patients were treated with RICE, and 34 received all 3 planned cycles. The CR rate was 53%, significantly better than the 27% CR rate (P = .01) achieved among 147 similar consecutive historical control patients with DLBCL treated with ICE; the PR rate was 25%. Febrile neutropenia was the most frequent grade 3 or 4 nonhematologic toxicity; it occurred in 7.5% of delivered cycles. No patient had RICE-related toxicity that precluded ASCT. The median number of CD34+ cells per kilogram mobilized was 6.3 × 106. Progression-free survival rates of patients who underwent transplantation after RICE were marginally better than those of 95 consecutive historical control patients who underwent transplantation after ICE (54% vs 43% at 2 years; P = .25). RICE appears to induce very high CR rates in patients with relapsed and refractory DLBCL; however, further studies are necessary to determine whether this treatment regimen will improve outcomes after ASCT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2003-11-3911

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 13

  1. Kewalramani T, Zelenetz AD, Hedrick EE, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood.2000;96: 2399-2404. · doi:10.1182/blood.v96.7.2399
  2. Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol.2001;19: 406-413. · doi:10.1200/jco.2001.19.2.406
  3. Prince HM, Imrie K, Crump M, et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. Br J Haematol.1996;92: 880-889. · doi:10.1046/j.1365-2141.1996.437976.x
  4. Moskowitz CH, Nimer SD, Glassman JR, et al. The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant.1999;23: 561-567. · doi:10.1038/sj.bmt.1701624
  5. Rosner B. Hypothesis Testing: Categorical Data: Fundamentals of Biostatistics. Belmont, CA: Wadsworth; 1994: 345-442.
  6. O'Brien JP, O'Keefe P, Alvarez A. The NHL-15 protocol for diffuse aggressive lymphomas: two-year median follow-up on the first 100 patients [abstract]. Proc Am Soc Clin Oncol.1995;14: 1230.
  7. Gribben JG, Goldstone AH, Linch DC, et al. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy. J Clin Oncol.1989;7: 1621-1629. · doi:10.1200/jco.1989.7.11.1621
  8. Vose JM, Anderson JR, Kessinger A, et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol.1993;11: 1846-1851. · doi:10.1200/jco.1993.11.10.1846
  9. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol.1995;13: 588-595. · doi:10.1200/jco.1995.13.3.588
  10. Caballero MD, Perez-Simon JA, Iriondo A, et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol.2003;14: 140-151. · doi:10.1093/annonc/mdg008
  11. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood.1988;71: 117-122. · doi:10.1182/blood.v71.1.117.117
  12. Girouard C, Dufresne J, Imrie K, et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol.1997;8: 675-680. · doi:10.1023/a:1008294725992
  13. Amar-Maman D, Mounier N, Manson J, et al. Evaluation of efficacy and toxicity of rituximab plus aracytin-platinum (R-DHAP) regimen in non-Hodgkin lymphoma (NHL) relapsing patients [abstract]. Blood.2002;100: 293a.

Cited by

See all 406

Metadata

Authors
Kewalramani, T., Zelenetz, A. D., Nimer, S. D., Portlock, C., Straus, D., Noy, A., O'Connor, O., Filippa, D. A., Teruya-Feldstein, J., Gencarelli, A., Qin, J., Waxman, A., Yahalom, J., & Moskowitz, C. H.
Venue
Blood
Publisher
American Society of Hematology
Published
2004-05-15
Volume
103
Issue
10
Pages
3684-3688
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2003-11-3911
OpenAlex
W2103563361
Cited by
406
References
22
FWCI
16.70
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. https://app.cochat.ai/papers/10.1182/blood-2003-11-3911
The paper
Kewalramani, T., Zelenetz, A. D., Nimer, S. D., Portlock, C., Straus, D., Noy, A., O'Connor, O., Filippa, D. A., Teruya-Feldstein, J., Gencarelli, A., Qin, J., Waxman, A., Yahalom, J., & Moskowitz, C. H. (2004). Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. https://doi.org/10.1182/blood-2003-11-3911

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.